RU2009121838A - Пероральная лекарственая форма, содержащая соединения тризамещенного глицерина - Google Patents
Пероральная лекарственая форма, содержащая соединения тризамещенного глицерина Download PDFInfo
- Publication number
- RU2009121838A RU2009121838A RU2009121838/15A RU2009121838A RU2009121838A RU 2009121838 A RU2009121838 A RU 2009121838A RU 2009121838/15 A RU2009121838/15 A RU 2009121838/15A RU 2009121838 A RU2009121838 A RU 2009121838A RU 2009121838 A RU2009121838 A RU 2009121838A
- Authority
- RU
- Russia
- Prior art keywords
- dosage form
- solid dosage
- pharmaceutical solid
- group
- form according
- Prior art date
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title claims 26
- 150000001875 compounds Chemical class 0.000 title claims 3
- 235000011187 glycerol Nutrition 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 title 1
- 239000007909 solid dosage form Substances 0.000 claims abstract 21
- 239000002552 dosage form Substances 0.000 claims abstract 13
- -1 tri-substituted glycerol compound Chemical class 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 208000026278 immune system disease Diseases 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000007888 film coating Substances 0.000 claims 5
- 238000009501 film coating Methods 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims 2
- 239000004925 Acrylic resin Substances 0.000 claims 1
- 229920000178 Acrylic resin Polymers 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- BMQVRJOWNGSIEG-UHFFFAOYSA-L calcium;icosanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCCCC([O-])=O BMQVRJOWNGSIEG-UHFFFAOYSA-L 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 150000002314 glycerols Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229940043348 myristyl alcohol Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229940075065 polyvinyl acetate Drugs 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85815706P | 2006-11-10 | 2006-11-10 | |
| US60/858,157 | 2006-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009121838A true RU2009121838A (ru) | 2010-12-20 |
Family
ID=39092201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009121838/15A RU2009121838A (ru) | 2006-11-10 | 2007-11-09 | Пероральная лекарственая форма, содержащая соединения тризамещенного глицерина |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20110110984A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2091520B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5352466B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN101610758A (cg-RX-API-DMAC10.html) |
| AT (1) | ATE546133T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2007316588B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2668919C (cg-RX-API-DMAC10.html) |
| DK (1) | DK2091520T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2382756T3 (cg-RX-API-DMAC10.html) |
| RU (1) | RU2009121838A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2008055996A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1745788A1 (de) * | 2005-07-22 | 2007-01-24 | KTB Tumorforschungsgesellschaft mbH | Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie |
| EP2117555B1 (en) * | 2006-12-20 | 2012-10-17 | Universitätsklinikum Hamburg-Eppendorf | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| EP1952803A1 (en) * | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
| TWI787523B (zh) * | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | 達沙替尼十二烷基硫酸鹽之結晶 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2619686C2 (de) | 1976-05-04 | 1986-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Verwendung eines Lysolecithins zur Tumorbehandlung |
| DE3530767A1 (de) * | 1985-08-28 | 1987-03-12 | Max Planck Gesellschaft | Mittel gegen multiple sklerose |
| DE3827974A1 (de) * | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen |
| DE3918082A1 (de) * | 1989-06-02 | 1991-01-24 | Max Planck Gesellschaft | Mittel gegen autoimmunerkrankungen |
| DE4000084A1 (de) | 1990-01-03 | 1991-07-04 | Medmark Pharma Gmbh | Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts) |
| WO1999030690A1 (en) * | 1997-12-15 | 1999-06-24 | Axia Therapeutics, Inc. | Oral delivery formulation |
| DE19822509A1 (de) * | 1998-05-19 | 1999-11-25 | Medmark Pharma Gmbh | Edelfosin zur Behandlung von Hirntumoren |
| DE19829448A1 (de) | 1998-07-01 | 2000-10-12 | Medmark Pharma Gmbh | 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen |
| US6583127B1 (en) * | 1998-12-21 | 2003-06-24 | Inkeysa. Sa | Use of etherlysophospholipids as antiinflammatory agents |
| CN1688291A (zh) * | 2002-02-01 | 2005-10-26 | 辉瑞产品公司 | 含有固体药物分散体的即刻释放剂型 |
| US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
-
2007
- 2007-11-09 DK DK07822468.0T patent/DK2091520T3/da active
- 2007-11-09 RU RU2009121838/15A patent/RU2009121838A/ru unknown
- 2007-11-09 EP EP07822468A patent/EP2091520B1/en not_active Not-in-force
- 2007-11-09 CN CNA2007800417728A patent/CN101610758A/zh active Pending
- 2007-11-09 US US12/514,390 patent/US20110110984A1/en not_active Abandoned
- 2007-11-09 AU AU2007316588A patent/AU2007316588B2/en not_active Ceased
- 2007-11-09 CN CN201310689824.XA patent/CN103816127A/zh active Pending
- 2007-11-09 WO PCT/EP2007/062180 patent/WO2008055996A1/en not_active Ceased
- 2007-11-09 JP JP2009535750A patent/JP5352466B2/ja not_active Expired - Fee Related
- 2007-11-09 CA CA2668919A patent/CA2668919C/en not_active Expired - Fee Related
- 2007-11-09 ES ES07822468T patent/ES2382756T3/es active Active
- 2007-11-09 AT AT07822468T patent/ATE546133T1/de active
-
2017
- 2017-02-22 US US15/439,443 patent/US20170157150A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2382756T3 (es) | 2012-06-13 |
| AU2007316588A1 (en) | 2008-05-15 |
| JP5352466B2 (ja) | 2013-11-27 |
| EP2091520A1 (en) | 2009-08-26 |
| CN101610758A (zh) | 2009-12-23 |
| CN103816127A (zh) | 2014-05-28 |
| CA2668919A1 (en) | 2008-05-15 |
| DK2091520T3 (da) | 2012-06-18 |
| JP2010509293A (ja) | 2010-03-25 |
| CA2668919C (en) | 2015-11-03 |
| AU2007316588B2 (en) | 2013-11-21 |
| ATE546133T1 (de) | 2012-03-15 |
| WO2008055996A1 (en) | 2008-05-15 |
| US20110110984A1 (en) | 2011-05-12 |
| EP2091520B1 (en) | 2012-02-22 |
| US20170157150A1 (en) | 2017-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7374781B2 (en) | Sustained release formulations containing acetaminophen and tramadol | |
| CN104379138B (zh) | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 | |
| JP3382940B2 (ja) | 中枢ドパミン欠乏状態を治療するための経口投与可能な医薬製剤 | |
| RU2006122517A (ru) | Фармацевтический состав для прямого прессования, предназначенный для перорального введения cci-779 | |
| RU2005114612A (ru) | Композиция, ингибирующая секрецию кислоты в желудке | |
| JPH02221219A (ja) | 接着性錠剤 | |
| WO2008072534A1 (ja) | マンニトール又は乳糖を含有する固形製剤 | |
| JP2006528237A (ja) | バレニクリンの医薬組成物 | |
| TW200407175A (en) | Dosage form of sodium IBUPROFEN | |
| HUP0000137A2 (hu) | Szabályozott hatóanyag-felszabadulású analgetikumot tartalmazó gyógyszerkészítmény | |
| CN102307575B (zh) | 含醋氯芬酸的控释口服药制剂及其制造方法 | |
| MXPA04011801A (es) | Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa. | |
| FR2735369A1 (fr) | Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside | |
| WO2007086891A1 (en) | Levetiracetam formulations and methods for their manufacture | |
| JP2006528604A (ja) | ６−ジメチルアミノメチル−１−（３−メトキシ−フェニル）−シクロヘキサン−１，３−ジオールを含む、有効物質徐放性医薬 | |
| CN102920707A (zh) | 一种复方抗结核制剂的制备工艺 | |
| JP5347092B2 (ja) | アンドログラフィス抽出物製剤 | |
| WO2010027010A1 (ja) | 有効成分が境界を有してなる医薬固形製剤 | |
| CN102526049A (zh) | 一种复方双氯芬酸钠缓释制剂及其制备方法 | |
| CA2627544A1 (en) | Formulations of quinolinones for the treatment of cancer | |
| JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
| KR101697773B1 (ko) | 독소필린을 포함하는 변형 방출 조성물 | |
| RU2008150430A (ru) | Фармацевтические композиции, содержащие комбинацию пиперидиноалканола и противоотечного средства | |
| JP2010509293A5 (cg-RX-API-DMAC10.html) | ||
| JP4947609B2 (ja) | 解熱鎮痛用組成物 |